BFBIO · BF Biosciences Limited
Financial Results for the Year Ended 2026-06-30
- Filed
- 29 September 2026 at 8:00 am
- Category
- Financials
- Sentiment
- Good
- Impact
- High
AI executive summary
BF Biosciences Limited reported its financial results for the year ended June 30, 2026, showing revenue growth to PKR 9,461.25 million and a profit after taxation of PKR 632.13 million, translating to an EPS of PKR 7.16.
Key takeaways
- Net revenue for the year ended June 30, 2026, increased to PKR 9,461,253,802 compared to PKR 5,837,466,169 in the previous year.
- Profit after taxation for the year rose to PKR 632,127,122 compared to PKR 447,147,356 in the prior year.
- Earnings per share (EPS) increased to PKR 7.16 for the year compared to PKR 5.52 for the previous year.
- Profit before income tax stood at PKR 1,056,765,067 compared to PKR 720,539,545 in the prior year.
- Operating profit (Profit from operations) was reported at PKR 1,173,370,881 compared to PKR 851,415,090 previously.
Filing details
Financial results
Annual · Audited · Standalone · 30 June 2026
Figures in Rupees
Reporting period
Year
- Income
- 9,461,253,802 (prior 5,837,466,169)
- Profit after tax
- 632,127,122 (prior 447,147,356)
- EPS
- 7.16 (prior 5.52)
Dividend and entitlement
- Type
- None
- Entitlement date
- 20 October 2026
- Book closure
- 21 October 2026 – 28 October 2026
- Notes
- No cash dividend, bonus shares, or right shares were recommended (NIL).
- #financial results
- #annual report
- #bfbios
- #earnings
This summary is AI-generated and may contain errors or omissions. Review the official PSX filing before making an investment decision.